This report details Sarepta's product revenue distribution in Q1 2026, highlighting the contributions of PMO therapies and Alevitus.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What revenue contribution came from PMO therapies versus Alevitus in Q1?
In Q1 2026, Sarepta reported total product revenue of $331 million, broken out as $229 million from PMO therapies (EXONDYS, VYONDYS, AMONDYS) and $102 million from Alevitus. 12
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
This analysis details Sarepta Therapeutics' 2026 net product revenue guidance ranging from $1.2B to $1.4B, primarily split between ELEVIDYS one-time gene therapy and the chronic PMO franchise. The breakdown highlights revenue drivers, patient segments, and the impact of educational initiatives.
Sources used
Research questionPlease provide the underlying model split for the $1.2B–$1.4B net product revenue guidance between ELEVIDYS prevalent ambulatory, incident patients, and PMOs.
Answer outline
📉📊 This report compares Reduction in Force (RIF) actions across Sarepta Therapeutics, Health Catalyst, Target Hospitality, and Strategic Education in Q2 2025, highlighting strategic, financial, and operational impacts. 🤝💼
Deep ResearchSources used
Research questionReduction in force
Answer outline
Hecla provides an update on its 2026 silver production guidance and outlines long-term strategies to reach 20 million ounces annually, emphasizing project ramp-ups and potential mine restorations.
Sources used
Research questionWhat revenue contribution came from PMO therapies versus Alevitus in Q1?
Answer outline
NIKE linked Q1 performance growth to strong football demand and growing basketball momentum. Management emphasized its retained football roster and World Cup-driven sales, while describing signature athletes, women’s basketball, and expanded distribution for Caitlin Clark’s debut shoe as key parts of its basketball growth strategy.
Sources used
Research questionWhat did management say about Football roster and basketball growth strategy?
Answer outline
Marvell attributes near-term data center margin pressure to the expanding mix of custom silicon, with management emphasizing that revenue levels and product mix drive gross margins each quarter. While the Q3 headwind is primarily a mix effect, management expects margins to stabilize as the custom ramp accelerates in H2 and broad-based growth supports margin expansion into fiscal 2028.
Sources used
Research questionWhat did management say about Data center margin drivers from custom mix?
Answer outline
Las Vegas Sands' Q2 2026 discussion attributes the quarter's results to a mix of headwinds from World Cup-related high-value patron volatility and seasonal tourism softness, offset by strong execution and strategic investments at Marina Bay Sands and in Macau. Management frames macro demand as a resilient baseline rather than the primary driver, with mass growth and improved service models underpinning the underlying earnings power despite short-term volatility.
Sources used
Research questionHow much of the quarter's performance in Marina Bay Sands and Macau do you attribute to macro/consumer demand versus World Cup effects or execution/investment in the properties?
Answer outline
Royal Caribbean's Q2 2026 remarks frame shorter itineraries as demand-led and economically viable, underpinned by investments in Perfect Day and Royal Beach Clubs to elevate the short-product. Management notes younger guests drive the trend, short trips achieving similar spend as longer cruises, with high demand and strong close-in bookings, while the classic 7-night itineraries remain popular in the Caribbean. Destinations and assets underpin a structured growth plan.
Sources used
Research questionWhat did management say about Shorter itineraries and Royal Beach Club investments?
Answer outline
Investors should read management’s “2H acceleration” as a qualitative uptick in the second half versus the first half, supported by guidance for sequential back-half growth and a Helios ramp that becomes more impactful in Q4. The Q2 107% YoY growth establishes the first-half baseline, with Q3 and Q4 expected to exceed it through supply and product timing.
Sources used
Research questionHow should investors interpret management’s view that data center AI growth will “accelerate” in the second half versus the first half, given Q2’s 107% year-over-year growth and the Q3/Q4 guidance trajectory?
Answer outline
Cloudflare's Q2 2026 results show monetization strengthening through a dual path: record new-logo bookings and sustained expansion among large customers. Despite no explicit nonhuman-traffic attribution, DBNR rose to 120% and large customers now account for about 73% of revenue, underscoring scale-driven monetization and the evolving model to monetize nonhuman and agent traffic via new charging rails like microtransactions.
Sources used
Research questionHow is the shift to nonhuman traffic affecting monetization: does it drive more new logos versus expanding existing customers, and is it boosting large customers more than smaller ones?
Answer outline
Western Digital outlines a dual-path outlook: LTA pricing remains contract-driven and predictable, particularly for nearline pricing, while offering upside in non-nearline contracts, and the exabyte growth trajectory remains robust at 25% plus, supported by 40TB ePMR ramp and upcoming HAMR and higher-capacity drives, with visibility extending through 2029–2031. Quarterly margins may vary due to LTA timing, but the long-term demand signal remains strong.
Sources used
Research questionWhat did management say about LTA pricing and exabyte growth outlook?
Answer outline
Pfizer's update highlights a $1.5 billion year-to-date non-COVID uplift driven by Eliquis alongside other products like NURTEC and Padcev, though the exact split isn’t quantified. Eliquis is projected to grow 20%–25% this year, while Padcev shows an initial acceleration that should moderate as la/mUC penetration matures, with upside potential from MIBC over time.
Sources used
Research questionWithin the $1.5 billion year-to-date increase in non-COVID revenue guidance, how much is due to Eliquis versus other products, and what is the updated Eliquis growth outlook? Also, with Padcev's expanded label, what is the expected growth path for that asset going forward?
Answer outline
Snap argues that its Specs investment is financially sensible, financed by eight quarters of positive free cash flow and paced to milestones within the existing expense outlook. The company contends that a first-mover, full-stack AR platform—backed by an AI-enabled operating model and a ready developer ecosystem—gives it a credible path to compete with Apple, Meta, and Alphabet.
Sources used
Research questionWhy is the Specs investment financially sensible for a company of Snap’s size, and what gives confidence that Snap can compete with larger players like Apple, Meta and Alphabet?
Answer outline
Dafinchi